WO1994005267A3 - Utilisation de carraghenanes comme antagonistes de facteur de croissance - Google Patents

Utilisation de carraghenanes comme antagonistes de facteur de croissance Download PDF

Info

Publication number
WO1994005267A3
WO1994005267A3 PCT/GB1993/001848 GB9301848W WO9405267A3 WO 1994005267 A3 WO1994005267 A3 WO 1994005267A3 GB 9301848 W GB9301848 W GB 9301848W WO 9405267 A3 WO9405267 A3 WO 9405267A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
carrageenans
factor antagonists
useful
disclosed
Prior art date
Application number
PCT/GB1993/001848
Other languages
English (en)
Other versions
WO1994005267A2 (fr
Inventor
Richard Michael Hoffman
Dietrich Herbert Walter Paper
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council filed Critical Medical Res Council
Priority to AU49726/93A priority Critical patent/AU4972693A/en
Publication of WO1994005267A2 publication Critical patent/WO1994005267A2/fr
Publication of WO1994005267A3 publication Critical patent/WO1994005267A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention se rapporte à une substance composée d'un carraghénane ou d'un de ses dérivés, utilisée comme inhibiteur ou suppresseur de facteur de croissance. Les substances décrites comme pouvant être utilisées comme inhibiteurs de facteur de croissance conviennent au traitement de tumeurs et autres états auxquels sont associés les facteurs de croissance.
PCT/GB1993/001848 1992-09-01 1993-09-01 Utilisation de carraghenanes comme antagonistes de facteur de croissance WO1994005267A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU49726/93A AU4972693A (en) 1992-09-01 1993-09-01 Use of carrageenans as growth factor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929218510A GB9218510D0 (en) 1992-09-01 1992-09-01 Improvements in or relating to hormone antagonists
GB9218510.7 1992-09-01

Publications (2)

Publication Number Publication Date
WO1994005267A2 WO1994005267A2 (fr) 1994-03-17
WO1994005267A3 true WO1994005267A3 (fr) 1994-04-28

Family

ID=10721240

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/001848 WO1994005267A2 (fr) 1992-09-01 1993-09-01 Utilisation de carraghenanes comme antagonistes de facteur de croissance

Country Status (3)

Country Link
AU (1) AU4972693A (fr)
GB (1) GB9218510D0 (fr)
WO (1) WO1994005267A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
FR2808687B1 (fr) * 2000-04-27 2003-12-05 Goemar Lab Sa Medicament contenant des substances polysaccharidiques pour l'activation de l'apoptose

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006396A2 (fr) * 1987-02-25 1988-09-07 Michael Neushul Procede de traitement d'infections par des virus du sida et d'autres retrovirus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006396A2 (fr) * 1987-02-25 1988-09-07 Michael Neushul Procede de traitement d'infections par des virus du sida et d'autres retrovirus

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 89, no. 3, 17 July 1978, Columbus, Ohio, US; abstract no. 22078w, R.G.P. PUGH-HUMPHREYS ET AL: "The effect of the macrophage cytotoxic agent iota-carrageenan on the growth of two transplantable murine ascites tumors." *
CHEMICAL ABSTRACTS, vol. 95, no. 9, 31 August 1981, Columbus, Ohio, US; abstract no. 73721g, E. OHTSUKA: "Activation of cytotoxic macrophages by carrageenan with special reference to iota- carrageenan." *
D.R. COOMBE ET AL.: "Analysis of the inhibition of tumour metastasis by sulphated polysaccharides.", INT. J. CANCER, vol. 39, no. 1, 1987, pages 82 - 88 *
H. NODA ET AL: "Antitumor activity of marine algae.", HYDROBIOLOGIA, vol. 204/205, 1990, pages 577 - 584 *
KEITH, MCBRIDE, STUART, EDS., PROC. EURES SYMP. MACROPHAGE CANCER, 1977, pages 142 - 154 *
NICHIDAI IGAKU ZASSHI, vol. 40, no. 6, 1981, pages 521 - 528 *
R. ISHAI-MICHAELI ET AL: "heparanase activity expressed by platelets, neutrophils and lymphoma cells releases active fibroblast growth factor from extracellular matrix.", CELL REGUL., vol. 1, no. 11, 1990, pages 833 - 842 *
T. MATSUMOTO ET AL.: "Growth inhibition of leukemia L-1210 ascites tumor by combination of carrageenan and mitomycin C in vivo.", J. PHARMACO-BIODYN., vol. 7, no. 7, 1984, pages 465 - 471 *

Also Published As

Publication number Publication date
GB9218510D0 (en) 1992-10-14
WO1994005267A2 (fr) 1994-03-17
AU4972693A (en) 1994-03-29

Similar Documents

Publication Publication Date Title
EP0433842A3 (en) 1,2,3-triazole derivatives active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
AU4032989A (en) Method and compositions for the treatment and prevention of septic shock
AU4041293A (en) Phenylderivate as inhibitors of atp citrate lyase
AU3102697A (en) Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
IL130349A0 (en) Substituted nitrogen containing heterocycles as inhibitors of P38 protein pinase and pharmaceutical compositions containing the same
AU5845394A (en) Biocompatible, surface modified materials and method of making the same
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
ZA9710245B (en) Heterocycles as inhibitors of leucocyte adhesion and as VLA-4-antagonists.
EP0690457A3 (fr) Solution à base de polyaniline, articles revêtus de polyaniline et procédés pour sa préparation
FI905228A0 (fi) Menetelmä mikro-organismien kasvun ja lisääntymisen ehkäisemiseksi
AU6157396A (en) Bis-arylsulfonylaminobenzamide derivatives and the use there of as factor xa inhibitors
PL321203A1 (en) Sulphonamide derivatives as inhibitors of kinurenin 3-hydroxylase, method of obtaining novel sulponamide compounds and drugs containing such compounds
EP0529854A3 (en) Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as hmg-coa reductase inhibitors
EP0678031A4 (fr) Inhibiteurs de croissance de tumeur derivee de tissu, procedes de preparation et utilisations de ces inhibiteurs.
EP0641209A4 (fr) NOUVEAUX DERIVES 17-ESTER, AMIDE ET CETONE DE 3-OXO-4-AZASTEROIDES UTILISES COMME INHIBITEURS DE 5a-REDUCTASE.
AU7270794A (en) Succinamide derivatives, processes for their preparation and their use as gelatinase and collagenase inhibitors
BG109411A (en) METHOD FOR OBTAINING HIV-PROTEZATE INHIBITORS
HUP9901984A3 (en) Naphthyl acetamides as spla2 inhibitors, use thereof and pharmaceutical compositions containing these compounds
IL126683A0 (en) Pharmaceutical composition and method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
EP0666849A4 (fr) Inhibiteurs aryliques et heteoarylmethoxyphenyliques de la biosynthese des leucotrienes.
AR244941A1 (es) Compuesto, composicion, procedimiento y uso antimicrobiano.
EP0656069A4 (fr) Inhibiteurs de la proliferation cellulaire, preparation et utilisation.
NO992504D0 (no) Sammensetninger for behandling av jord, fremgangsmÕte for fremstilling derav, samt anvendelse
NO931400D0 (no) Derivater av adipogeneseinhiberende faktor, samt fremstilling og anvendelse derav

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA